Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/ bevacizumab failure: A real-world study”

키워드

참고문헌 (21)

1. Finn RS, "Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
2. Chon YE, "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab", bevacizumab failure : A real-world study, 2024, pp.30, 345~359
3. Yoo C, "Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma : A multinational multicenter retrospective study", Liver Cancer, 10, pp.107~114 (2021)
4. Hiraoka A, "Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology : multicenter retrospective study", Sci Rep, 11, pp.16663~ (2021)
5. Aoki T, "Exploratory analysis of lenvatinib therapy in patients with unresectable hepatocellular carcinoma who have failed prior PD-1", PD-L1 checkpoint blockade, 2020, pp.12, 3048~
6. Osa A, "Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients", JCI Insight, 3, pp.e59125~ (2018)
7. Spranger S, "Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity", Nature, 523, pp.231~235 (2015)
8. Ruiz de Galarreta M, "β-Catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma", Cancer Discov, 9, pp.1124~1141 (2019)
9. Harding JJ, "Prospective genotyping of hepatocellular carcinoma : Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies", Clin Cancer Res, 25, pp.2116~2126 (2019)
10. Morita M, "Immunological microenvironment predicts the survival of the patients with hepatocellular carcinoma treated with anti-PD-1 antibody", Liver Cancer, 10, pp.380~393 (2021)
11. Garcia-Diaz A, "Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression", Cell Rep, 19, pp.1189~1201 (2017)
12. Yamauchi M, "Tumor fibroblast growth factor receptor 4level predicts the efficacy of lenvatinib in patients with advanced hepatocellular carcinoma", Clin Transl Gastroenterol, 11, pp.e00179~ (2020)
13. Maruta S, "Potential of lenvatinib for an expanded indication from the REFLECT trial in patients with advanced hepatocellular carcinoma", Liver Cancer, 9, pp.382~396 (2020)
14. Ogasawara S, "Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma : safety, efficacy and prognostic factors", Invest New Drugs, 33, pp.729~739 (2015)
15. McNamara MG, "Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a metaanalysis", Eur J Cancer, 105, pp.1~9 (2018)
16. Kuzuya T, "Clinical outcomes of ramucirumab as posttreatment following atezolizumab", bevacizumab combination therapy in advanced hepatocellular carcinoma, 2022, pp.42, 1905~1910
17. Yoo C, "Regorafenib in previously treated advanced hepatocellular carcinoma : Impact of prior immunotherapy and adverse events", Liver Int, 40, pp.2263~2271 (2020)
18. Chan SL, "Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment", J Hepatol, 81, pp.258~264 (2024)
19. Frenette C, "How to choose second-line treatment for hepatocellular carcinoma", Clin Adv Hematol Oncol, 19, pp.726~729 (2021)
20. Zhu AX, "Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma", Nat Med, 28, pp.1599~1611 (2022)
21. Zeng Q, "Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma : a multicentre retrospective study", Lancet Oncol, 24, pp.1411~1422 (2023)

관련 논문AI추천